^
    18h
    Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance (clinicaltrials.gov)
    P2, N=59, Recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Apr 2026 --> Sep 2026 | Trial primary completion date: Apr 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • Cyramza (ramucirumab) • pemetrexed
    19h
    Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial. (PubMed, Int J Cancer)
    The phase II RAMIRIS trial compared RAM plus paclitaxel with RAM plus FOLFIRI (5-fluororuracil, leucovorin and irinotecan) in this setting...Elevated PlGF-particularly its early increase during RAM-based therapy-was associated with shortened survival and may represent a dynamic marker of unfavorable prognosis in advanced gastric/GEJ adenocarcinoma. Given the exploratory nature of this analysis, these findings should be considered hypothesis-generating and require validation in independent biomarker-driven studies.
    P2 data • Journal
    |
    CA9 (Carbonic anhydrase 9)
    |
    paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • leucovorin calcium
    6d
    Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer (clinicaltrials.gov)
    P2, N=26, Completed, Samsung Medical Center | Recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab)
    6d
    Impact of prior nivolumab on treatment outcomes of taxane plus ramucirumab in advanced gastric cancer. (PubMed, Jpn J Clin Oncol)
    Prior ICI exposure may not significantly affect the efficacy or safety of subsequent taxane plus RAM therapy.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • Cyramza (ramucirumab) • oxaliplatin
    7d
    SYSKY-2023-1262-02: Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=32, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial completion date: Sep 2026 --> Sep 2028 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    AiTan (rivoceranib) • Teysuno (gimeracil/oteracil/tegafur) • AiRuiLi (adebrelimab)
    7d
    24-Week Recurrence Rate of Gout Following Firsekibart Treatment (clinicaltrials.gov)
    P=N/A, N=264, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New trial • Real-world evidence
    |
    Jin Beixin (firsekibart)
    8d
    Lung-MAP Sub-Study: Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) (clinicaltrials.gov)
    P2, N=66, Recruiting, SWOG Cancer Research Network | Trial completion date: May 2027 --> Jun 2028 | Trial primary completion date: May 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification
    |
    Tagrisso (osimertinib) • Cyramza (ramucirumab) • Tabrecta (capmatinib)
    8d
    Apatinib inhibits synovial sarcoma progression and angiogenesis via VEGFR2-mediated AKT/FOXO3A and ERK1/2/FOXM1 signaling pathways. (PubMed, Cell Death Discov)
    In vivo, apatinib markedly suppressed xenograft tumor growth and modulated the corresponding signaling pathways. Collectively, our findings identify apatinib as a promising therapeutic agent that disrupts interconnected survival and angiogenic networks in SS.
    Journal
    |
    KDR (Kinase insert domain receptor) • FOXM1 (Forkhead Box M1) • FOXO3 (Forkhead box O3) • NOS3 (Nitric oxide synthase 3)
    |
    AiTan (rivoceranib)
    9d
    Targeting USP10/SCD1 axis by RAF265 suppresses lipogenesis and induced ferroptosis in head and neck squamous cell carcinoma. (PubMed, Cell Death Discov)
    Notably, we discover that RAF265, a compound already approved by the FDA, effectively inhibits USP10 activity, leading to decreased SCD1 expression and lipogenesis, which then suppresses tumor growth and enhances ferroptosis in both in vitro and in vivo models of HNSCC. Collectively, these results underscore the critical role of the E2F4/USP10/SCD1 pathway in modulating ferroptosis and driving HNSCC progression, suggesting that targeting this axis with RAF265 may offer a promising strategy for therapeutic intervention in this malignancy.
    Journal
    |
    SCD (Stearoyl-CoA Desaturase) • USP1 (Ubiquitin Specific Peptidase 1)
    |
    RAF265
    10d
    Efficacy and Safety of Scheduled Versus As-Needed Firsekibart Administration for the Prevention of Gout Recurrence: A Multicenter, Open-Label, Randomized Controlled Trial (clinicaltrials.gov)
    P=N/A, N=118, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New trial
    |
    Jin Beixin (firsekibart)
    10d
    A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors (clinicaltrials.gov)
    P=N/A, N=208, Not yet recruiting, Henan Cancer Hospital
    New trial
    |
    AFP (Alpha-fetoprotein)
    |
    5-fluorouracil • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • leucovorin calcium
    13d
    Metachronous hepatocellular carcinoma after partial response of advanced intrahepatic cholangiocarcinoma treated with radiotherapy combined with apatinib and camrelizumab: a case report. (PubMed, Front Oncol)
    Radiotherapy combined with anti-angiogenic and immunotherapy is an effective option for advanced unresectable iCCA. It also emphasizes that active pathological biopsy is essential for new hepatic lesions after iCCA remission to clarify diagnosis and avoid misdiagnosis-induced inappropriate treatment.
    Journal
    |
    AFP (Alpha-fetoprotein)
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)